Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century
Corresponding Author
Dianne Pulte
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Correspondence: Dianne Pulte, Division of Hematology, Department of Medicine, Thomas Jefferson University, 1015 Chestnut Street Suite 1321, Philadelphia, PA 19107, USA.
E-mail: [email protected]
Search for more papers by this authorLina Jansen
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Search for more papers by this authorAdam Gondos
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Search for more papers by this authorKatharina Emrich
Cancer Registry of Rhineland-Palatinate Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Johannes Gutenberg University Mainz, Mainz, Germany
Search for more papers by this authorAlexander Katalinic
Cancer Registry of Schleswig-Holstein, Lübeck, Germany
Search for more papers by this authorHermann Brenner
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Search for more papers by this authorthe GEKID Cancer Survival Working Group
Search for more papers by this authorCorresponding Author
Dianne Pulte
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Correspondence: Dianne Pulte, Division of Hematology, Department of Medicine, Thomas Jefferson University, 1015 Chestnut Street Suite 1321, Philadelphia, PA 19107, USA.
E-mail: [email protected]
Search for more papers by this authorLina Jansen
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Search for more papers by this authorAdam Gondos
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Search for more papers by this authorKatharina Emrich
Cancer Registry of Rhineland-Palatinate Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Johannes Gutenberg University Mainz, Mainz, Germany
Search for more papers by this authorAlexander Katalinic
Cancer Registry of Schleswig-Holstein, Lübeck, Germany
Search for more papers by this authorHermann Brenner
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
Search for more papers by this authorthe GEKID Cancer Survival Working Group
Search for more papers by this authorSummary
Treatment for Hodgkin lymphoma (HL) is more aggressive in Germany than in the United States (US) and differences in treatment may lead to differences in population level survival. Patients diagnosed with HL in 11 German states in 1997–2006 were included in the analyses and were compared to similar analyses from patients in the Surveillance, Epidemiology, and End Results database in the US. Period analysis was used to calculate 5-year relative survival for the time period of 2002–2006 overall and by gender, age and histology. Overall 5-year relative survival for patients with HL in Germany was 84·3%, compared to 80·6% for the US. Survival was highest in patients aged 15–29 years at 97·9% and decreased with age to 57·5% at age 60 + Survival for men and women, respectively, was 84·7% and 84·1% in Germany and 78·2% and 83·6% in the US. 5-year relative survival for patients diagnosed with HL in Germany was close to 100% for younger patients. Survival of HL patients in the US was lower than in Germany overall, but was comparable in older patients and in women. Population-based studies with longer follow-up are still needed to examine effects of late toxicity on long term survival.
References
- Arias, E. (2002) United States life tables, 2000. National Vital Statistics Reports, 51, 1–38.
- Armitage, J.O., Blerman, P.J., Vose, J.M., Anderson, J.R., Weisenburger, D.D., Kessinger, A., Reed, E.C., Vaughan, W.P., Coccia, P.F. & Purtilo, D.T. (1991) Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. American Journal of Medicine, 91, 605–611.
- Behringer, K. & Diehl, V. (2005) Twenty-five years clinical trials of the german hodgkin study group (GHSG). European Journal of Haematology. Supplementum, 66, 21–25.
10.1111/j.1600-0609.2005.00450.x Google Scholar
- Brenner, H. & Gefeller, O. (1996) An alternative approach to monitoring cancer patient survival. Cancer, 78, 2004–2010.
10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-# CAS PubMed Web of Science® Google Scholar
- Brenner, H. & Hakulinen, T. (2002) Up-to-date long-term survival curves of patients with cancer by period analysis. Journal of Clinical Oncology, 20, 826–832.
- Brenner, H. & Hakulinen, T. (2006) Up-to-date and precise estimates of cancer patient survival: Model-based period analysis. American Journal of Epidemiology, 164, 689–696.
- Brenner, H. & Holleczek, B. (2011) Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancer notified by death certificate only. Cancer Epidedmiology Biomarkers and Prevention, 20, 2480–2486.
- Brenner, H., Soederman, B. & Hakulinen, T. (2002a) Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. International Journal of Epidemiology, 31, 456–462.
- Brenner, H., Gefeller, O. & Hakulinen, T. (2002b) A computer program for period analysis of cancer patients ruvival. European Journal of Cancer, 38, 690–695.
- Brenner, H., Gefeller, O. & Hakulinen, T. (2004) Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realization and applications. European Journal of Cancer, 40, 326–335.
- Brenner, H., Gondos, A. & Pulte, D. (2008) Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood, 111, 2977–2983.
- Brenner, H., Francisci, S., de Angelis, R., Marcos-Gragera, R., Verdecchia, A., Gatta, G., Allemani, C., Ciccolallo, L., Coleman, M., Sant, M. & for the EUROCARE Working Group (2009) Long-term survival expectations of cancer patients in Europe in 2000-2002. European Journal of Cancer, 45, 1028–1041.
- Centers for Disease Control and Prevention (CDC) (2008) HIV prevalence estimates-United States, 2006. Morbidity and Mortality Weekly Report, 57, 1073–1076.
- Collins, S.R., Schoen, C., Kriss, J.L., Doty, M.M. & Mahato, B. (2007) Rite of passage? Why young adults become uninsured and how new policies can help. Issue Brief (Commonwealth Fund), 26, 1–16.
- Corazziari, I., Quinn, M. & Capocaccia, R. (2004) Standard cancer patient population for age standardising survival ratios. European Journal of Cancer, 40, 2307–2316.
- DeVita, V.T. Jr (1981) The consequences of the chemotherapy of Hodgkin's disease: the 10th David A Kamosfky Memorial Lecture. Cancer, 47, 1–13.
10.1002/1097-0142(19810101)47:1<1::AID-CNCR2820470102>3.0.CO;2-2 PubMed Web of Science® Google Scholar
- Diehl V, Franklin J, Pfreundschuh, M., Lathan, B., Paulus, U., Hsaenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.K., Dühmke, E., Loeffler, M. & for the German Hodgkin's Lymphoma Study Group (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386–2395.
- Ederer, F. & Heise, H. (1959) Instructions to IBM 650 Programmers in Processing Survival Computations. National Cancer Institute, Bethesda, MD.
- Frel, E. III, De Vita, V.T., Moxley, J.H. III & Carbone, P.P. (1966) Approaches to improving the chemotherapy of Hodgkin's disease. Cancer Research, 26, 1284–1289.
- Gondos, A., Holleczek, B., Arndt, V., Stegmaier, C., Ziegler, H. & Brenner, H. (2007) Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Annals of Oncology, 18, 1253–1259.
- Gondos, A., Bray, F., Hakulinen, T., Brenner, H. & and the EUNICE Survival Working Group (2009) Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Annals of Oncology, 20, 564–573
- Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506–1514.
- Hiripi, E., Gondos, A., Emrich, K., Holleczek, B., Katalinic, A., Luttmann, S., Sirri, E. & Brenner, H. (2012) GEKID cancer survival working group. Survival from common and rare cancers in Germany in the early 21st century. Annals of Oncology, 23, 472–479.
- Koroukian, S.M., Bakaki, P.M. & Raghavan, D. (2012) Survival disparities by Medicaid status: an analysis of 8 cancers. Cancer, 118, 4271–4279.
- Mariotto, A., Capocaccia, R., Verdecchia, A., Micheli, A., Feuer, E.J., Pickle, L. & Clegg, L.X. (2002) Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes and Control, 13, 101–111.
- Martin, S., Ulrich, C., Munsell, M., Taylor, S., Lange, G. & Bleyer, A. (2007) Delays in cancer diagnosis in underinsured young adults and older adolescents. The Oncologist, 12, 816–824.
- Pulte, D., Gondos, A., Redaniel, M.T. & Brenner, H. (2011) Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. The Oncologist, 16, 663–671.
- Robert Koch Institut (2010) Zum Welt-AIDS-Tag 2010. Epidemiologisches Bulletin: Aktuelle Daten und Informationen zu Infektionskrankheiten und Public Health, 46, 453–462.
- Santoro, A., Bonadonna, G., Valagussa, P., Zucali, R., Viviani, S., Villani, F., Pagnoni, A.M., Bonfante, V., Crippa, F., Tess, J.D.T. & Banfi, A. (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. Journal of Clinical Oncology, 5, 27–37.
- Scholz, M., Engert, A., Franklin, J., Josting, A., Diehl, V., Hasenclever, D., Loeffler, M. & German Hodgkin's Lymphoma Study (2011) Group. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Annals of Oncology, 22, 681–688.
- Verdacchi, A., Francisci, S., Brenner, H., Gatta, G., Micheli, A., Mangone, L., Kunkler, I. & for the EUROCARE-4 Working Group (2007) Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. The Lancet Oncolology, 8, 784–796.
- Yung, R.L., Chen, K., Abel, G.A., Gesten, F.C., Roohan, P.J., Boscoe, F.P., Sinclair, A.H., Schymura, M.J. & Schrag, D. (2011) Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollment. The Oncologist, 16, 1082–1091.
Citing Literature
